Clinical TrialJun 2, 2026, 07:12 AM
Rezolute's Ersodetug Phase 3 upLIFT Study: 6 of 8 Participants Respond
AI Summary
Rezolute, Inc. announced positive interim data from its ongoing open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. The study is 50% enrolled with 8 participants, and 6 of these have already met the primary endpoint, showing at least a 50% reduction in intravenous glucose requirements, with complete discontinuation in these responders. The drug has been well-tolerated with no drug-related adverse events reported. Topline results for the fully enrolled study are anticipated in the second half of 2026.
Key Highlights
- Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism shows positive interim data.
- Study is 50% enrolled, with 8 of 16 planned participants currently enrolled.
- 6 of 8 enrolled participants met the primary endpoint responder criterion.
- These 6 participants achieved at least a 50% reduction in IV glucose requirements.
- All 6 responders also achieved complete discontinuation of intravenous glucose.
- Ersodetug has been well-tolerated with no drug-related adverse events reported.
- Topline results for the fully enrolled study are expected in H2 2026.
Price Impact
More from RZLT